DK2683371T3 - Forbindelser og fremgangsmåder til forbedring af forringet endogen fibrinolyse ved anvendelse af histondeacetylasehæmmere - Google Patents

Forbindelser og fremgangsmåder til forbedring af forringet endogen fibrinolyse ved anvendelse af histondeacetylasehæmmere Download PDF

Info

Publication number
DK2683371T3
DK2683371T3 DK12713772.7T DK12713772T DK2683371T3 DK 2683371 T3 DK2683371 T3 DK 2683371T3 DK 12713772 T DK12713772 T DK 12713772T DK 2683371 T3 DK2683371 T3 DK 2683371T3
Authority
DK
Denmark
Prior art keywords
histondeacetylase
deteriored
fibrinolyse
endogen
inhibitors
Prior art date
Application number
DK12713772.7T
Other languages
English (en)
Inventor
Pia Larsson
Niklas Bergh
Sverker Jern
Original Assignee
Cereno Scient Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cereno Scient Ab filed Critical Cereno Scient Ab
Application granted granted Critical
Publication of DK2683371T3 publication Critical patent/DK2683371T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK12713772.7T 2011-03-09 2012-03-09 Forbindelser og fremgangsmåder til forbedring af forringet endogen fibrinolyse ved anvendelse af histondeacetylasehæmmere DK2683371T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161464809P 2011-03-09 2011-03-09
US201161464776P 2011-03-09 2011-03-09
US201161628339P 2011-10-28 2011-10-28
PCT/GB2012/000229 WO2012120262A1 (en) 2011-03-09 2012-03-09 Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors

Publications (1)

Publication Number Publication Date
DK2683371T3 true DK2683371T3 (da) 2021-01-18

Family

ID=45952577

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12713772.7T DK2683371T3 (da) 2011-03-09 2012-03-09 Forbindelser og fremgangsmåder til forbedring af forringet endogen fibrinolyse ved anvendelse af histondeacetylasehæmmere

Country Status (11)

Country Link
US (4) US20140051716A1 (da)
EP (1) EP2683371B1 (da)
CN (2) CN110063951A (da)
AU (2) AU2012226586B2 (da)
CA (1) CA2866333C (da)
DK (1) DK2683371T3 (da)
ES (1) ES2842970T3 (da)
HU (1) HUE053300T2 (da)
MX (1) MX2013010329A (da)
PL (1) PL2683371T3 (da)
WO (1) WO2012120262A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417828D0 (en) * 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
SG10201901916WA (en) * 2014-09-03 2019-04-29 Pharmacyclics Llc Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
US20200179381A1 (en) * 2016-04-08 2020-06-11 Cereno Scientific Ab Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
ES2969021T3 (es) * 2016-04-08 2024-05-16 Cereno Scient Ab Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de las mismas
TWI659949B (zh) 2016-05-16 2019-05-21 臺北醫學大學 組蛋白去乙醯酶6抑制劑及其用途
CA3087565A1 (en) 2018-01-09 2019-07-18 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
AU2020283590A1 (en) 2019-05-31 2022-01-20 Viracta Subsidiary, Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
USRE38506E1 (en) 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2002030879A2 (en) 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
AU2002243231A1 (en) * 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
ITMI20011733A1 (it) * 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
ES2307909T3 (es) 2002-03-13 2008-12-01 Janssen Pharmaceutica Nv Derivados de piperazinil, piperidinil y morfolinil como nuevos inhidbidores de la histona deacetilasa.
ATE398105T1 (de) 2002-03-13 2008-07-15 Janssen Pharmaceutica Nv Carbonylamino- derivativate als neue inhibitoren von histone deacetylase
IL164007A0 (en) 2002-03-13 2005-12-18 Janssen Pharmaceutica Nv New inhibitors of histone deacetylase
DK1591109T3 (da) 2004-04-30 2008-10-06 Topotarget Germany Ag Formulering, der omfatter histondeacetylaseinhibitorer, der udviser tofaset frigivelse
ITMI20040876A1 (it) * 2004-04-30 2004-07-30 Univ Degli Studi Milano Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
WO2006017215A2 (en) 2004-07-12 2006-02-16 Merck & Co., Inc. Histone deacetylase inhibitors
US20080221157A1 (en) 2004-07-12 2008-09-11 Istituto Di Ricerche Di Biologia Molecolare P Ange Amide Derivatives as Inhibitors of Histone Deacetylase
CA2573413C (en) 2004-07-12 2010-02-09 Merck & Co., Inc. Histone deacetylase inhibitors
AU2005271841A1 (en) 2004-07-12 2006-02-16 Merck & Co., Inc. Inhibitors of histone deacetylase
EP1771167A4 (en) 2004-07-19 2010-04-21 Merck Sharp & Dohme INHIBITORS OF HISTONE DEACETYLASE
MX2007001120A (es) 2004-07-28 2007-03-15 Janssen Pharmaceutica Nv Derivados de indolil alquil sustituidos como nuevos inhibidores de la histona desacetilasa.
US8569277B2 (en) * 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
AR050926A1 (es) 2004-09-03 2006-12-06 Astrazeneca Ab Derivados de benzamida como inhibidores de la histonadesacetilasa(hdac)
GB0500828D0 (en) 2005-01-15 2005-02-23 Astrazeneca Ab Benzamide derivatives
WO2006117165A2 (en) * 2005-05-02 2006-11-09 Friedrich-Alexander-Universität Erlangen-Nürnberg Means and methods for the treatment of head injuries and stroke
EP1743654A1 (en) * 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
JP2009507081A (ja) * 2005-09-07 2009-02-19 ブレインセルス，インコーポレイティド ＨＤａｃ阻害による神経発生の調整
BRPI0615690B8 (pt) * 2005-09-08 2021-05-25 Mei Pharma Inc compostos heterocíclicos de hidroxamato, seus usos e composição farmacêutica
DK1943232T3 (da) 2005-10-27 2011-08-29 Janssen Pharmaceutica Nv Kvadratsyrederivater som inhibitorer af histondeacetylase
ES2376121T3 (es) 2006-01-19 2012-03-09 Janssen Pharmaceutica, N.V. Derivados de heterociclilalquilo como nuevos inhibidores de histona deacetilasa.
US8114876B2 (en) 2006-01-19 2012-02-14 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
JP5137849B2 (ja) 2006-01-19 2013-02-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしての置換インドリル−アルキル−アミノ−誘導体
US8101616B2 (en) 2006-01-19 2012-01-24 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
DE602007001190D1 (de) 2006-01-19 2009-07-09 Janssen Pharmaceutica Nv Aminophenylderivate als neue inhibitoren von histondeacetylase
ES2402213T3 (es) 2006-01-19 2013-04-29 Janssen Pharmaceutica N.V. Derivados de piridina y pirimidina como inhibidores de histona desacetilasa
US20100061984A1 (en) * 2006-01-20 2010-03-11 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
CA2641951A1 (en) * 2006-04-06 2007-10-11 Novartis Ag Combination of organic compounds
WO2008154402A2 (en) * 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
US20090270497A1 (en) 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
CN101897687B (zh) * 2009-05-26 2012-07-04 中国科学院上海生命科学研究院 丙戊酸钠治疗肝脏炎症相关疾病的新用途
WO2011113013A2 (en) * 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions

Also Published As

Publication number Publication date
CN110063951A (zh) 2019-07-30
US20170020874A1 (en) 2017-01-26
ES2842970T3 (es) 2021-07-15
CN103648492A (zh) 2014-03-19
CA2866333A1 (en) 2012-09-13
AU2017203028B2 (en) 2018-11-15
EP2683371B1 (en) 2020-10-21
MX2013010329A (es) 2014-03-12
CA2866333C (en) 2020-12-29
PL2683371T3 (pl) 2021-04-19
AU2012226586B2 (en) 2017-04-13
US20140051716A1 (en) 2014-02-20
US20230094176A1 (en) 2023-03-30
AU2012226586A1 (en) 2013-10-03
HUE053300T2 (hu) 2021-06-28
AU2017203028A1 (en) 2017-05-25
US20210060014A1 (en) 2021-03-04
WO2012120262A1 (en) 2012-09-13
EP2683371A1 (en) 2014-01-15

Similar Documents

Publication Publication Date Title
DK3468197T3 (da) Fremgangsmåde til interforudsigelse og indretning dertil
DK3223284T3 (da) Fremgangsmåde til dannelse og opretholdelse af højydelses-frc
DK2709613T4 (da) Fremgangsmåder til behandling af hcv
CO6970602A2 (es) Inhibidores de quinasa
DK3141542T3 (da) Substituerede benzaldehydforbindelser og fremgangsmåder til anvendelse deraf ved øgning af vævsiltning
DK2710007T3 (da) Kinasehæmmere
DK2794907T3 (da) Fremgangsmåder og materialer til vurdering af tab af heterozygositet
DK3329775T3 (da) Fremgangsmåder til syntese af diarylthiohydantoin- og diarylhydantoinforbindelser
CO6950481A2 (es) Inhibidores de proteínas quinasas
CO6801649A2 (es) Polipeptidos anticuerpos que antagonizan cd40
DK2800565T3 (da) Carbamatforbindelser og fremgangsmåder til fremstilling og anvendelse af samme
DK2920149T3 (da) 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf
BR112013016154A2 (pt) inibidores de faah
DK2766392T3 (da) Fremgangsmåde til oprensning af antistoffer
DK2753334T3 (da) Fap-aktiverede proteasomhæmmere til behandling af solide tumorer
DK2776833T3 (da) Cobinder-understøttet testfremgangsmåde
DK2489670T3 (da) Fremgangsmåde til fremstilling af aminosyre-chelatforbindelser, aminosyre-chelatforbindelser og anvendelse af aminosyre-chelatforbindelser
DK3412687T3 (da) Fremgangsmåder til behandling af dlbcl
BR112014007958A2 (pt) método
DK3322183T3 (da) Fremgangsmåde til intraforudsigelse af video
BR112014001237A2 (pt) método
BR112014001765A2 (pt) método
DK3985979T3 (da) Fremgangsmåde til bestemmelse af referenceenhed
DK2787799T3 (da) Plade med indlejret komponent og fremgangsmåde til fremstilling af samme og pakke med plade med indlejret komponent
BR112014009795A2 (pt) método